

**DRAFT LyFE Lymphoma Forum of Excellence 2024:**  
**What's new in lymphoid neoplasias?**  
 Bellinzona, 2–4 February 2024

**DAY 1 – FRIDAY, 2.2.2024**

<i>Chairperson: E. Zucca</i>		
10:30–11:00	Current definition of the most common lymphoma entities	L. Mazzucchelli
11:00–11:30	The immune–microenvironment of lymphomas	A. Tzankov
11:30–12:00	Introduction to basic molecular biology for clinicians	A. Mensah
12:00–13:00	Key note lecture - 25 years of antibody therapy for lymphoma	P. Johnson
13:00–14:00	Lunch	
14:00–15:00	Interactive workshop – Lymphoma in pregnancy	F. Peccatori (TBC)
<i>Chairperson: F. Cavalli</i>		
15:00–15:30	PET metrics: where do we stand?	L. Ceriani
15:30–16:00	Modern radiotherapy approaches	L. Deantonio
16:00–16:20	What's new in Hodgkin Lymphoma?	P. Johnson
16:20–16:40	What's new in primary mediastinal B–cell lymphoma	E. Zucca
16:40–17:00	Break	
17:00–18:30	Discussion of cases of participants	

**DAY 2 – SATURDAY, 3.2.2024**

<i>Chairperson: D. Rossi</i>		
08:40–09:00	What's new in chronic lymphocytic leukemia	D. Rossi
09:00–09:20	What's new in Waldenström macroglobulinemia	A. Condoluci
09:20–09:40	What's new in follicular lymphomas	M.C. Piroso
09:40–10:00	What's new in marginal zone lymphoma	E. Zucca
10:00–10:20	What's new in mantle–cell lymphomas	M.C. Piroso
10:20–11:00	Break	
11:00–11:20	What's new in aggressive B–cell lymphomas	A. Stathis
11:20–11:40	What's new in (nodal) peripheral T–cell lymphomas	S. Luminari
11:40–12:00	Amyloidosis	B. Gerber
12:00–13:30	Discussion of cases of participants	
13:30–14:40	Lunch	
<i>Chairperson: A. Stathis</i>		
14:40–15:00	What's new in primary CNS lymphoma	A. Ferreri
15:00–15:20	What's new in secondary CNS lymphoma	A. Ferreri
15:20–15:40	What's new in cutaneous B– and T–cell lymphoma	H. Beltraminelli
15:40–16:00	What's new in intestinal T–cell lymphoma and other extranodal entities	S. Luminari
16:00–16:30	Break	
16:30–18:00	Discussion of cases of participants	

**DAY 3 – SUNDAY, 4.2.2024**

<i>Chairperson E. Zucca</i>		
09:00–09:30	Mechanisms of lymphoma resistance to treatment	F. Bertoni
09:30–10:00	Targeted treatments in lymphoma	A. Stathis
10:00–10:30	Bispecific antibodies in myeloma	E. Lerch
10:30–11:00	CAR–T cell	F. Simonetta
11:00–11:15	Concluding remarks & End of the meeting	E. Zucca